Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Salarius Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Salarius Pharmaceuticals, Inc.

SLRX

Salarius Pharmaceuticals, Inc.

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, including protein degraders and inhibitors. Its pipeline features drugs like SP-3164 and SP-2577, aimed at high unmet need cancers such as hematological malignancies and pediatric sarcomas. The company collaborates with academic institutions, holds key patents, and advances through regulatory pathways to bring innovative treatments to oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Salarius Pharmaceuticals, Inc.

1
1
Salarius Pharmaceuticals, Inc. Decoy Therapeutics Reports $2.2 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
Salarius Pharmaceuticals, Inc. Decoy Therapeutics Reports $12.5 Million Net Loss and Strategic Developments in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Salarius Pharmaceuticals, Inc. Salarius Pharmaceuticals Reports Q3 2025 Financial Results, Net Loss Decreases

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Salarius Pharmaceuticals, Inc. Salarius Pharmaceuticals Reports Decreased Losses and Pursues Merger with Decoy Therapeutics

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Salarius Pharmaceuticals, Inc. Salarius Pharmaceuticals Reports $1.71 Million Net Loss in Q1 2025, Pursues Merger with Decoy Therapeutics

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Salarius Pharmaceuticals, Inc. Salarius Pharmaceuticals Reports Decreased Losses and Enters Merger Agreement with Decoy Therapeutics

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Salarius Pharmaceuticals, Inc. Salarius Pharmaceuticals Reports Improved Financials, Net Loss Decline, and Strategic Review Amid Cash Constraints

Via official filing (AI summary) | over 1 year ago | 0 comments